Evidence map›Paper›PMID 22754355›Full record

ArticleInternational journal of molecular sciences2012

The three dimensional Quantitative Structure Activity Relationships (3D-QSAR) and docking studies of curcumin derivatives as androgen receptor antagonists.

Guanhong Xu, Yanyan Chu, Nan Jiang, Jing Yang, Fei Li

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. A Review of Curcumin and Its Derivatives as Anticancer Agents.International journal of molecular sciences · 2019
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guanhong XuSchool of Pharmacy, Nanjing Medical University, Nanjing 210029, China.
Yanyan ChuSchool of Pharmacy, Nanjing Medical University, Nanjing 210029, China.
Nan JiangSchool of Pharmacy, Nanjing Medical University, Nanjing 210029, China.
Jing YangSchool of Pharmacy, Nanjing Medical University, Nanjing 210029, China.
Fei LiSchool of Pharmacy, Nanjing Medical University, Nanjing 210029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen receptor antagonists have been proved to be effective anti-prostate cancer agents. 3D-QSAR and Molecular docking methods were performed on curcumin derivatives as androgen receptor antagonists. The bioactive conformation was explored by docking the potent compound 29 into the binding site of AR. The constructed Comparative Molecular Field Analysis (CoMFA) and Comparative Similarity Indices Analysis (CoMSIA) models produced statistically significant results with the cross-validated correlation coefficients q(2) of 0.658 and 0.567, non-cross-validated correlation coefficients r(2) of 0.988 and 0.978, and predicted correction coefficients r(2) (pred) of 0.715 and 0.793, respectively. These results ensure the CoMFA and CoMSIA models as a tool to guide the design of novel potent AR antagonists. A set of 30 new analogs were proposed by utilizing the results revealed in the present study, and were predicted with potential activities in the developed models.

Indexed as

Androgen Receptor AntagonistsAntineoplastic AgentsBinding SitesCell Line, TumorCell ProliferationCurcuminDrug DesignHumansMaleMolecular Docking SimulationProstatic NeoplasmsQuantitative Structure-Activity RelationshipAndrogen Receptor AntagonistsAntineoplastic AgentsCurcuminandrogen receptor antagonistsCoMFACoMSIAcurcumin derivativesdocking

Identifiers

PMID22754355
PMCPMC3382773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.